Guard Therapeutics plans to raise SEK 150 million through a rights issue to advance its kidney protective treatment RMC-035, with 80% of the issue already covered by commitments and guarantees.
Guard Therapeutics has dosed the first European patient in its Phase 2b POINTER study, evaluating RMC-035 for kidney protection during open-heart surgery.
Guard Therapeutics' Phase 2 AKITA study results, published in eClinicalMedicine, demonstrate a statistically significant kidney-protective effect of RMC-035 in patients undergoing open-heart surgery.
Guard Therapeutics has announced the dosing of the first patient in its phase 2b clinical study, POINTER, evaluating RMC-035 as a kidney-protective treatment during open-heart surgery. The study, starting in Canada and expanding to Europe, aims to determine the optimal dosing regimen and target population for RMC-035.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.